Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.55 |
| ▸ | CKS1B | P61024 | 1/20 | 0.53 |
| ▸ | SKP1 | P63208 | 1/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587106 | 0.94 | MAPT (0.63) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL3409507 | 0.87 | ADRB2 (0.56) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL24990320 | 0.86 | MAPT (0.61) | MAPTALDH1A1LMNAGPR119MEN1 | |
| SCHEMBL5235594 | 0.86 | GPR119 (0.69) | MAPTALDH1A1LMNAGPR119CKS1B | |
| SCHEMBL13281422 | 0.85 | MAPT (0.62) | MAPTALDH1A1LMNAGPR119CKS1B | |
| SCHEMBL5231173 | 0.85 | GPR119 (0.70) | MAPTALDH1A1LMNAGPR119CKS1B | |
| SCHEMBL15475168 | 0.85 | MAPT (0.59) | MAPTALDH1A1LMNAGPR119CKS1B | |
| SCHEMBL5655442 | 0.85 | GPR119 (0.73) | MAPTALDH1A1LMNAGPR119CKS1B | |
| SCHEMBL5231271 | 0.84 | MAPT (0.67) | MAPTALDH1A1LMNAGPR119CKS1B | |
| SCHEMBL5573222 | 0.84 | MAPT (0.76) | MAPTALDH1A1LMNAGPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | MAPT 4452/4885ALDH1A1 1073/4885LMNA 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.